Molecular characterization of coagulation factor XII deficiency in a Japanese family

Summary

We report the identification in a Japanese family of a novel homozygous W486C mutation in the protease domain of coagulation factor XII (FXII), which was associated with the reduction of plasma FXII activity and antigen level to less than 5% of normal. Sequences of each exon for FXII gene was analysed in family members by polymerase chain reaction (PCR) amplification followed by a direct sequencing method. Sequence analysis showed a homozygous substitution of G to C at nucleotide position 10587 (cDNA position 1458) in proband’s FXII gene, resulting in a Trp to Cys substitution in the catalytic domain of FXII. PCR-fragment length polymorphism analysis of 55 healthy volunteers showed no such mutation. Transient expression of FXII in HK-293T cells and analysis of FXII antigen in culture media and cell lysates showed reduced secretion of mutant protein by more than 84% relative to that of wild type protein although the intracellular contents were similar. Our results suggest that the reduced secretion of FXII protein was due to incorrect folding caused by the introduction of Cys486. We designated this mutation as FXII Mie-1.

Keywords

Coagulation factor XII - W486C mutation - protein folding

• References

• 1 Ratnoff OD, Colopy JE. Familial hemorrhagic trait associated with deficiency of clot-promoting fraction of plasma. J Clin Invest 1955; 34: 602-13.
• 2 Griffin JH, Cochrane CG. Human factor XII (Hageman factor). Methods Enzymol 1976; 45: 56-65.
• 3 Fujikawa K, Davie EW. Human factor XII (Hagman factor). Methods Enzymol 1981; 80: 198-211.
• 4 Tans G, Rosing J. Structural and functional characterization of factor XII. Semin Thromb Haemost 1987; 13: 1-14.
• 5 Haanen C, Hommes F, Benraad H, Morselt G. A case of Hageman factor deficiency and a method to purify the factor. Thromb Diath Haemorrh 1960; 5: 201-7.
• 6 Didisheim P. Hageman factor deficiency (Hageman trait). Arch Intern Med 1962; 110: 74-81.
• 7 Ikkala E, Myllylä G, Nevanlinna HR. Rare congenital coagulation factor defects in Fin-land. Scand J Haematol 1971; 8: 210-5.
• 8 Glucck HI, Rochill W. Myocardial infarction in a patient with a Hageman (factor XII) defect. Ann Intern Med 1966; 64: 390-6.
• 9 McPherson RA. Thromboembolism in Hage-man trait. Am J Clin Pathol 1977; 68: 420-3.
• 10 Hellstern P, Köhler M, Schmengler K, Doe-necke P, Wenzel E. Arterial and venous thrombosis and normal response to streptokinase treatment in a young patient with severe Hage-man factor deficiency. Acta Haematol 1983; 69: 123-6.
• 11 Lodi S, Isa L, Pollini E, Ferrari BA, Scalvini A. Defective intrinsic fibrinolytic activity in a patient with severe factor XII deficiency and myocardial infarction. Scand J Haematol 1984; 33: 80-82.
• 12 Royle NJ, Nigli M, Cool D, MacGillivray RT, Hamerton JL. Structure gene encoding human FXII is located at 5q33-qter. Somatic Cell Mo-lec Genet 1988; 14: 217-21.
• 13 Cool DE, Edgell CJ, Louie GV, Zoller MJ, Brayer GD, Mac Gillivray RT. Characterization of human blood coagulation factor XII cDNA Prediction of the primary structure of factor XII and the tertiary structure of beta-FXIIa. J Biol Chem 1985; 260: 13666-76.
• 14 Tripodi M, Citarella F, Guida S, Galeffi P, Fan-otoni A, Cortese R. cDNA sequence coding for human coagulation factor XII (Hageman). Nucleic Acids Res 1986; 13: 3146
• 15 Cool DE, MacGillivray RT. Characterization of human blood coagulation factor XII gene. Intron/exon gene organization and analysis of the 5’-prime flanking region. J Biol Chem 1987; 262: 13662-73.
• 16 Bernadi F, Marchetti G, Patracchini P. et al. Factor XII gene alteration in Hageman trait detected by Taq I restriction enzyme. Blood 1987; 69: 1421-4.
• 17 Hofferbert S, Müller J, Köstering H, von Oh-len WD, Schloesser M. A novel 5’ upstream mutation in the factor XII gene associated with Taq I restriction site in an Alu repeat in factor XII deficient patient. Hum Genet 1996; 97: 838-41.
• 18 Miyata T, Kawabata S, Iwanaga S, Takahashi I, Alving B, Saito H. Coagulation factor XII (Hageman factor) Washington D.C.: Inactive factor XIIa results from Cys-571 Ser substitution. Proc Natl Acad Sci USA 1989; 86: 8319-22.
• 19 Hovinga JK, Schaller J, Stricker H. et al. Coagulation factor XII Locarno: The function defect is caused by the amino acid substitution Arg 353 Pro leading to loss of a kallikrein cleavage site. Blood 1994; 84: 1173-81.
• 20 Schlosser M, Zeerleder S, Lutze G. et al. Mutations in the human factor XII gene. Blood 1997; 90: 3967-77.
• 21 Kanaji T, Okamura T, Kamura T, Niho Y, Sugiyama M. Molecular analysis of a family with factor XII deficiency. Identification of 126 Arg to Pro substitution. Blood 1995; 86: 876a.
• 22 Kanaji T, Okamura T, Osaki K. et al. A common genetic polymorphism (46C to T substitution) in the 5’-untranslated region of coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998; 91: 2010-4.
• 23 Kondo S, Tokunaga F, Kuwano S, Oono Y, Kumagai S, Koide T. Factor XII Tenri, a novel cross reacting material negative factor XII deficiency, occurs through a proteasome-mediated degradation. Blood 1999; 93: 4300-8.
• 24 Kanaji T, Kanaji S, Osaki K. et al. Identification and characterization of two novel mutations (Q421 and R123 P) in congenital factor XII deficiency. Thromb Haemost 2001; 86: 1409-15.
• 25 Kopito PR. ER quality control: The cytoplasmic connection. Cell 1997; 88: 427-30.
• 26 Kim PS, Arvan P. Endocrinopathies in the family of endoplasmic reticulum (ER) storage diseases: Disorders of protein trafficking and the role of ER molecular chaperones. Endocrine Rev 1998; 19: 173-202.